Diagnostic Application of Volatile Organic Compounds as Potential Biomarkers for Detecting Digestive Neoplasia: A Systematic Review

Catalin, Dima Augustin; Vasile, B; Dima, Alina

doi:10.3390/diagnostics11122317

Cited by 24 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21]. The nature of these diseases related special smells is caused by different VOCs, which is demonstrated by the nobel prize laureate that Linus Pauling's pioneer work on the breath analysis in 1971 using gas-liquid partition chromatography [22]. In the past 50 years, thousands of volatile biomarkers, i.e., VOCs, associated with various diseases or lesions, have been identified and classified from multi-body sources (Fig.…”

Section: Introductionmentioning

confidence: 99%

Volatolomics in healthcare and its advanced detection technology

Jian

et al. 2022

Nano Res.

View full text Add to dashboard Cite

Various diseases increasingly challenge the health status and life quality of human beings. Volatolome emitted from patients has been considered as a potential family of markers, volatolomics, for diagnosis/screening. There are two fundamental issues of volatolomics in healthcare. On one hand, the solid relationship between the volatolome and specific diseases needs to be clarified and verified. On the other hand, effective methods should be explored for the precise detection of volatolome. Several comprehensive review articles had been published in this field. However, a timely and systematical summary and elaboration is still desired. In this review article, the research methodology of volatolomics in healthcare is critically considered and given out, at first. Then, the sets of volatolome according to specific diseases through different body sources and the analytical instruments for their identifications are systematically summarized. Thirdly, the advanced electronic nose and photonic nose technologies for volatile organic compounds (VOCs) detection are well introduced. The existed obstacles and future perspectives are deeply thought and discussed. This article could give a good guidance to researchers in this interdisciplinary field, not only understanding the cutting-edge detection technologies for doctors (medicinal background), but also making reference to clarify the choice of aimed VOCs during the sensor research for chemists, materials scientists, electronics engineers, etc.

show abstract

Section: Introductionmentioning

confidence: 99%

Volatolomics in healthcare and its advanced detection technology

Jian

et al. 2022

Nano Res.

View full text Add to dashboard Cite

show abstract

“…It has been reported that acetone, ammonia, benzaldehyde, butanal, butyric acid, decane, dimethyl/hydrogen sulfide, dimethyl/undecane, ethylbenzene, 1,2,3-tri-methylbenzene, 1,2-di-methylbenzene, furfural, hexanoic acid, hexane/hexanal, isoprene, phenol, pentanoic acid, p-xylene, and tetradecane are associated with digestive cancers. 51 Metabolites can be absorbed in the blood and exhaled directly. They may also be absorbed and further metabolized in liver, kidney, and other internal organ systems and their microbiomes and exhaled as final stable states.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Ability of Volatile Organic Compounds in Digestive Cancer: A Systematic Review With Meta-Analysis

Yang

Mou

2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Volatile organic compounds (VOCs) have been involved in cancer diagnosis via breath, urine, and feces. We aimed to assess the diagnostic ability of VOCs on digestive cancers. Methods: We systematically reviewed prospective clinical trials evaluating VOCs’ diagnostic ability on esophageal, gastric, colorectal, hepatic, and pancreatic cancer (PC). Databases including PubMed and Ovid-Medline were searched. Results: A total of 35 trials with 5314 patient-times qualified for inclusion. The pooled sensitivity of VOCs diagnosing gastroesophageal cancer from healthy controls is 0.89 (95% confidence interval [CI]: 0.82-0.94), the pooled specificity is 0.890 (95% CI: 0.84-0.93), and area under the curve (AUC) of the summary receiver operating characteristic curve is 0.95 (95% CI: 0.93-0.95). The pooled sensitivity of VOCs diagnosing colorectal cancer from heathy controls is 0.92 (95% CI: 0.85-0.96), the pooled specificity is 0.88 (95% CI: 0.77-0.94), and the AUC is 0.96 (95% CI: 0.94-0.97). The pooled sensitivity of VOCs distinguishing gastrointestinal (GI) cancer from precancerous lesions is 0.84 (95% CI: 0.67-0.92), the pooled specificity is 0.74 (95% CI: 0.43-0.91), and the AUC is 0.87 (95% CI: 0.84-0.89). The pooled sensitivity of VOCs diagnosing hepatocellular carcinoma is 0.68 (95% CI: 0.52-0.81), the pooled specificity is 0.81 (95% CI: 0.47-0.96), and the AUC is 0.78 (95% CI: 0.74-0.81). The pooled sensitivity of VOCs diagnosing PC is 0.88 (95% CI: 0.80-0.93), the pooled specificity is 0.82 (95% CI: 0.62-0.93), and the AUC is 0.92 (95% CI: 0.89-0.94). Conclusions: Volatile organic compounds have potential role in diagnosing GI cancer with comparatively high sensitivity, specificity, and AUC (PROSPERO registration number: CRD42021260039).

show abstract

“…Although most commonly used biomarkers are blood-based, CSF, urine, saliva or breath are other frequent sources of biological material for diagnostics purposes. In this issue, Dima et al [ 4 ] performed a systematic review of the use of volatile organic compounds (VOCs) in exhaled breath as non-invasive biomarkers in digestive neoplasia.…”

Section: Discussionmentioning

confidence: 99%